NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

Here are the research funds Dr. Vivek Subbiah have received since 2016. Ask yourself the question which company can provide almost all the technologies complementary to DCVax-L. That company should be the other one LP will choose as another collaborator.

2016
Universal Genomic Testing Needed to Win the War Against CancerGenomics IS the Diagnosis
https://jamanetwork.com/journals/jamaoncology/article-abstract/2513253

Dr Subbiah reports research funds from Novartis, Bayer, GSK, Nanocarrier, Vegenics, Northwest Biotherapeutics, Berghealth, Incyte, Fujifilm

2018
Cytokines Produced by Dendritic Cells Administered Intratumorally Correlate with Clinical Outcome in Patients with Diverse Cancers
https://aacrjournals.org/clincancerres/article/24/16/3845/277824/Cytokines-Produced-by-Dendritic-Cells-Administered

V. Subbiah reports receiving commercial research grants from AbbVie, Amgen, Bayer, BERG, Blueprint Medicines, D3, Fujifilm, GlaxoSmithKline, Idera Pharmaceuticals, Incyte, Loxo Oncology, MultiVir, NanoCarrier, Northwest Biotherapeutics, Novartis, Pfizer, PharmaMar, and Vegenics.

2020
Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies
https://aacrjournals.org/mct/article/19/5/1165/92857/Genomics-Morphoproteomics-and-Treatment-Patterns

V. Subbiah is a consultant/advisory board member at LOXO Oncology/Eli Lilly, Helsinn, R-Pharma US, Incyte, QED, Novartis, Medimmune and reports receiving a commercial research grant from LOXO Oncology/Eli Lilly, Blueprint Medicines, Fujifilm, Pharmamar, D3, Pfizer, Multivir, Amgen, ABBVIE, Agensys, Boston Biomedical, Idera, Turning Point therapeutics, Exelixis, Inhibrx, Altum, Medimmune, Dragonfly Therapeutics, Takeda, Roche/Genentech, Novartis, Bayer, GSK, Nanocarrier, Berghealth, Incyte, and Northwest Biotherapeutics.

2022
Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study
https://aacrjournals.org/clincancerres/article/28/13/2762/704976/Antitumor-Activity-of-Lurbinectedin-a-Selective

V. Subbiah reports grants from PharmaMar during the conduct of the study. V. Subbiah also reports grants from PharmaMar, Eli Lilly/LOXO Oncology, Blueprint Medicines Corporation, Turning Point Therapeutics, Boston Pharmaceuticals, and Helsinn Pharmaceuticals; clinical trial research grants from Roche/Genentech, Bayer, GlaxoSmithKline, Nanocarrier, Vegenics, Celgene, Northwest Biotherapeutics, Berg Health, Incyte, Fujifilm, D3, Pfizer, MultiVir, Amgen, AbbVie, Alfasigma, Agensys, Boston Biomedical, Idera Pharma, Inhibrx, Exelixis, Blueprint Medicines, Altum, Dragonfly Therapeutics, Takeda, National Comprehensive Cancer Network, NCI-CTEP, University of Texas MD Anderson Cancer Center, Turning Point Therapeutics, Boston Pharmaceuticals, Novartis, PharmaMar, and Medimmune;

2024
Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer
https://www.nature.com/articles/s41698-024-00563-4

V.S. reports research funding/grant support (to institution) for conducting clinical trials from AbbVie, Agensys, Inc., Alfasigma, Altum, Amgen, Bayer, BERG Health, Blueprint Medicines Corporation, Boston Biomedical, Inc., Boston Pharmaceuticals, D3 Bio, Inc., Dragonfly Therapeutics, Inc., Exelixis, Fujifilm, GlaxoSmithKline, Idera Pharmaceuticals, Inc., Incyte Corporation, Inhibrx, Loxo Oncology, MedImmune, MultiVir, Inc., NanoCarrier, Co., National Comprehensive Cancer Network, NCI-CTEP, Northwest Biotherapeutics, Novartis, PharmaMar, Pfizer, Relay Therapeutics, Roche/Genentech, Takeda, Turning Point Therapeutics, and Vegenics Pty Ltd.